Exploring isoindolin-1-ones as potential CDK7 inhibitors using cheminformatic tools.

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Oncology

Background:

• Breast cancer remains a leading cause of cancer death in women.
• Targeting Cyclin-dependent kinases (CDKs) with small molecule inhibitors is a key strategy for anti-cancer drug discovery.
• Isoindolin-1-ones are heterocyclic compounds with known therapeutic potential.

Purpose of the Study:

• To virtually screen a library of isoindolinone derivatives as potential inhibitors of CDK7.
• To evaluate the binding affinity, stability, and pharmacokinetic properties of promising candidates.

Main Methods:

• Virtual screening using molecular docking of 48 isoindolinone compounds against CDK7.
• In-depth analysis of top candidates (ligands 7 and 14) using molecular dynamics simulations (MDS), fragment molecular orbital (FMO), and density functional theory (DFT).
• Pharmacokinetic parameter prediction.

Main Results:

• Molecular docking identified isoindolinones with high binding affinity (up to -10.1 kcal/mol) and hydrogen bonding interactions with CDK7.
• MDS confirmed the stability of the docked poses for ligands 7 and 14 over 100 ns.
• DFT studies indicated that ligands 7 and 14 are chemically reactive soft molecules, favorable for anti-cancer activity, with FMO highlighting key amino acid interactions (LYS139, LYS41).

Conclusions:

• Isoindolin-1-one derivatives demonstrate significant potential as effective CDK7 inhibitors.
• The identified compounds exhibit promising binding characteristics and drug-like properties, superior to existing CDK7 inhibitors.
• This scaffold represents a promising starting point for the development of novel anti-breast cancer agents.